Histone deacetylase inhibitors such as vorinostat enhance gemtuzumab ozogamicin efficacy
in vitro. We, therefore, investigated vorinostat+ gemtuzumab ozogamicin for adults aged 60 …

Background Epigenetic therapeutics such as the histone deacetylase (HDAC) inhibitor,
vorinostat, and the DNA methyltransferase (DNMT) I inhibitor, azacitidine, sensitize AML …

Background: In this study, the effectiveness and safety of combining gemtuzumab
ozogamicin (GO) with an abbreviated schedule of standard induction chemotherapy were …

This trial tested the safety and efficacy of a regimen consisting of hydroxyurea followed by
azacitidine, 75 mg/m2 for 7 days, and gemtuzumab ozogamicin, 3 mg/m2 on day 8, in older …

Purpose There has been little survival improvement in older patients with acute myeloid
leukemia (AML) in the last two decades. Improving induction treatment may improve the rate …

Purpose This randomized trial evaluated the efficacy and toxicity of sequential gemtuzumab
ozogamicin (GO) and standard chemotherapy in older patients with newly diagnosed acute …

The prognosis of acute myeloid leukemia (AML) in older adults is generally poor. Standard
cytotoxic chemotherapy is usually poorly tolerated and provides dismal results in this patient …

BACKGROUND: Elderly patients with acute myeloid leukemia (AML) are generally unable to
withstand the rigors of intensive induction chemotherapy and its attendant complications …

Gemtuzumab ozogamicin (GO), an anti-CD33 monoclonal antibody conjugated to
calicheamicin, is effective as single agent in the treatment of poor risk acute myeloid …

Reprise: gemtuzumab ozogamicin for older patients with acute myeloid leukemia. - Abstract -
Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …